Bioptimus, a pioneer in AI foundation models, has raised $76 million in funding with $41 million in the last round by Cathay Innovation. This funding will help ramp up Bioptimus’s efforts to improve biological science through its multi-scale, multi-modal AI base model which is due out in 2025.
As its founding principle, Bioptimus has set its goal in transcending the present barrier that has long discouraged the integration of multiple and distinct biological fields. Being based on big data analysis of molecules, cells, tissues, organisms, and others, Bioptimus’s platform provides a comprehensive view at biology boosting ideas and discoveries.
July saw Bioptimus announce H-Optimus-0, currently the biggest AI foundation model in pathology. It has been shown that this model performs better than competitors: the benchmarks established in gene expression prediction and ovarian cancer subtyping using the models developed at Harvard Medical School and the University of Leeds are outstanding.
Strengthening on this success, the new model to be developed by Bioptimus is further expected to support simulation of biology at a much larger scale and is likely to devise breakthroughs in several related areas including pharma, biotechnology and cosmetic industries as well.
“What we are building is not just a technological breakthrough; it’s a transformative tool for understanding biology in its full complexity,” said Jean-Philippe Vert, co-founder and CEO of Bioptimus. “Essentially, it’s like the GPT of biology, but instead of generating text, we’re simulating biology.”
This next-gen model will transform the drug discovery environment, precision medicines, and the prediction of disease outcomes. Besides the provision of healthcare; it is a revolutionary solution for cosmetics, farming and other sectors. It will also aid the company in partnering with the pharmaceutical leaders, improving datasets, as well as developing the multi-modal AI platform.
Cathay Innovation’s Jacky Abitbol also noted on the firm’s unorthodox strategy citing, “By integrating data across multiple scales and modalities, Bioptimus is paving the way for groundbreaking innovations across industries.”
For Bioptimus cutting-edge biological research activities, its vision to scale biology at new levels is set to revolutionise how industries should solve problems, making it one of the greatest impacts in the age of artificial intelligence research.